Semaglutide's kidney and CV benefits consistent across MRA use, despite subgroup size imbalance

Type 2 Diabetes (T2D) with Chronic Kidney Disease (CKD) presents significant cardiovascular and renal risks. Mineralocorticoid receptor antagonists (MRAs) are a standard treatment for CKD, but their interaction with newer agents like semaglutide (a GLP-1R agonist) is crucial for optimizing patient outcomes. Understanding if semaglutide's benefits are consistent across MRA use helps guide combination therapy strategies, ensuring efficacy is maintained with existing therapies.

This paper responds to comments on a prespecified exploratory analysis from the FLOW trial, which evaluated semaglutide 1 mg once weekly in Type 2 Diabetes patients with CKD. The original analysis assessed kidney, cardiovascular, and mortality outcomes by baseline mineralocorticoid receptor antagonist (MRA) use. The authors address concerns regarding subgroup size imbalance and the interpretation of interaction analyses in the context of the trial's limited power.

The original prespecified analysis of the FLOW trial demonstrated consistent benefits of semaglutide on kidney, cardiovascular, and mortality outcomes, irrespective of baseline MRA use. The authors reiterate their intention was to show consistent benefit, not a difference in effect between subgroups. They acknowledge the limited power for interaction analyses due to subgroup size imbalance, as noted by Liu et al.

The core finding from the original analysis, which this response reinforces, is that semaglutide's positive effects on renal and cardiovascular endpoints are maintained whether patients are on MRAs or not. The authors also discuss methodological considerations, such as the redundancy of post hoc power calculations and the implications of multivariable-adjusted sensitivity analyses on HR interpretation, opting to report results without such adjustments for the purposes of this specific interaction analysis.